1Dymedex Market Development Consulting, Strategic Market Assessment, Barrx, 30 de outubro de 2014. Referências 1, 3-5, 7-13, 15, 16, 20-23, 25, 27-29, 40-44, 46, 48-50, 54-59, 62-66, 68-75, 78, 79, 81, 82, 87-89, e 97 da lista de citação completa, acesse http://www.medtronic.com/giclaims
2Spechler SJ. Barrett’s esophagus. N Engl J Med. 2002;346(11):836-42.
3Dymedex Market Development Consulting, GERD Sizing and Segmentation for pH Testing, 13 de fevereiro de 2015.
4SEER Cancer Statistics Factsheets: Esophageal Cancer. National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/statfacts/html/esoph.html.
5De Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. 2010;59:1030-6.
6Hvid-Jensen F, Pedersen L, Drewes AM, Sorensen HT, Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375-83.
7Wani S, Falk G, Hall M, Gaddam S, Wang A, Gupta N, et al. Patients with nondysplastic Barrett’s esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol. 2011;9(3):220-7.
8Shaheen NJ, Richter JE. Barrett’s oesophagus. Lancet. 2009;373(9666):850-61.
9Spechler SJ, Souza RF. Barrett’s esophagus. NEJM. 2014;371:836-45.
10Shaheen NJ, Falk GW, Iyer PG, Gerson LB, ACG Clinical Guideline: Diagnosis ans Management of Barret's esophagus. The American Journal Of Gastroinstentinal Endoscopy.2018;87 (41.9087-351)
11Wani S, Qumseya B, Sultan S, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer. Gastrointestinal Endoscopy. 2018;87(4):907-931
12"Whats Are the Key Statistics about Cancer of the Esophagus?" Cancer.org. 2006. American Cancer Socuety. Acessado em outubro de 2007.
13Gilbert EW, Luna RA, Harrison VL, Hunter JG. Barrett’s esophagus: a review of the literature. J Gastrointest Surg. 2011;15:708-18.
14Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311(12)1209-17. doi:10.1001/jama.2014.2511.
15Wolf WA, Pasricha S, Cotton C, Li N, Triadafilopoulos G, Raman Muthusamy V, et al. Incidence of Esophageal Adenocarcinoma and Causes of Mortality After Radiofrequency Ablation of Barrett’s Esophagus. Gastroenterology. 2015;149(7):1752-1761.
16Barrios E. Sierra MS, MUserri C. FormanD. The burden of eshophageal cancer in Central and South America Cacer Epidemiology, 2016:44 (Supplement 1): S53-s61